BiotechTube
Home/Pipeline/DO-1

DO-1

Not specified

Pre-clinicalActive

Key Facts

Indication
Not specified
Phase
Pre-clinical
Status
Active
Company
DeuterOncology

About DeuterOncology

DeuterOncology is a private, clinical-stage biotechnology company leveraging deuteration chemistry to develop improved kinase inhibitors. Its lead asset, DO-2, is a deuterated, brain-penetrant MET/RAS pathway inhibitor currently in Phase I dose expansion for MET-altered solid tumors, with preliminary data showing promising safety and activity. The company, founded by Dr. Timothy Perera, has secured Series A financing and grant funding to advance its pipeline, aiming to establish a best-in-class therapy in the competitive MET inhibitor landscape.

View full company profile

Therapeutic Areas

OncologyLung Cancer

Other Not specified Drugs

DrugCompanyPhase
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
Collaborative Program with FerringPharmaBiomeResearch
Lighthouse Pilot ProductCipheromePilot
Nitric Oxide + Collagen DeliveryJellagenResearch
UndisclosedAutheraPre-clinical
BP1003Bio-Path HoldingsPreclinical
mRNA Therapeutics Platform ApplicationLupagenResearch
PHYRAGOHanda PharmaceuticalsApproved
TASCENSO ODTHanda PharmaceuticalsApproved
AxulinHousey Pharmaceutical Research LaboratoriesCommercial
PBI-04711Phoenix BiotechnologyPre-clinical